Compass Therapeutics, Inc. (CMPX) stock
CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.61−0.05 (-8.28%)
Close on Nov 17, 2026Market cap $109.26MP/E –Yield –
Compass Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Compass Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$56.38M. For fiscal 2025 it was -$49.17M. The highest annual figure on record is -$21.23M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$49.17M | – |
| FY2024 | Dec 31, 2024 | -$44.90M | – |
| FY2023 | Dec 31, 2023 | -$40.65M | – |
| FY2022 | Dec 31, 2022 | -$34.34M | – |
| FY2021 | Dec 31, 2021 | -$21.23M | – |
| FY2020 | Dec 31, 2020 | -$26.91M | – |
| FY2019 | Dec 31, 2019 | -$32.21M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$14.91M | – |
| Q1 FY2026 | Mar 31, 2026 | -$17.35M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.25M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.86M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.83M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.23M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.16M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.10M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.75M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.89M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.36M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.93M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.12M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.23M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.70M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.97M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.54M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.14M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.44M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.82M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.24M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.73M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.66M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.18M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.30M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.77M | – |
| Q2 FY2019 | Sep 30, 2019 | -$6.73M | – |
| Q1 FY2019 | Jun 30, 2019 | -$19.70M | – |
See a number that looks wrong?